|
|
 |
|
Viewing report
|
|
|
|
Current and Future Therapies For Lung Cancer - A Therapeutic & Competitive Insight
Bioseeker, March 2006, Pages: 101
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed. Progress profiles and structured information will alow you to pin-point your knowledge-base in a most costeffective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventisï Taxotere (docetaxel), Bristol-Myers Squibbïs Paraplatin (carboplatin) and Eli Lillyïs Gemzar (gemcitabine).
Scope of this report
- Thorough examination of status and impact of many novel drugs in development
- Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
- Case studies on major lung cancer drugs on market
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development.
- Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date.
- Gain insight into the current challenges and commercial opportunities associated with lung cancer
Drugs included in this study
Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474
Methodology
The information structure in this report is based on our tactical information surveillance tool. Companies have been identified through the extensive information surveillance of more than 10 000 life science companies that represent the groundwork of our in-house company database. The analysis is based upon public information during 2003-2006. The amount of information varies, since established big pharmaceutical companies on the market, generally expose less information, as part of their business strategy. In contrast to small biotech companies, whose success is dependent on more direct exposure and on establishing themselves in the existing market.
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Targeted Therapeutics in Non-Small Cell Lung Cancer
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Chinese Markets for Lung Cancer Treatment Drugs
Analytical Tool - Current & Future Lung Cancer Therapeutics
Treatment Algorithms 2001: Lung Cancer
Drug Delivery in Cancer - Technologies, Markets and Companies
Breast Cancer - Therapeutic And Competitive Insights
Top 7 Cancer Indications - Therapeutic & Competitive Insights
|
|
|
|
